000000_Synthonics_ChyloCureBook_Rev031919

• Hemp derived CBD and CBDa attractive and growing niche – Estimated at $580 million in 2018 * – Expected to exceed $2.0 billion in 2020 – Could exceed $20.0 billion in 2022 *

– Recent de-scheduling should accelerate growth of industry • As medical use evolves need for “pharmaceutical grade” product grows – Ease of predictable and precise dosing – Increased and consistent potency – Pure product that retains benefits of “entourage effect” – Improved absorption and performance – Increasing recognition of diverse biological effects * Brightfield Group (9/2018)

Opportunity